If your child has been diagnosed as small for their gestational age (SGA)—meaning they were born smaller than expected for how long the pregnancy lasted—you may have heard about growth hormone therapy. A new analysis of 30 years of scientific research on this treatment offers reassuring insights into how this field has matured and what it means for families like yours in Singapore and across Asia.
Understanding the Research Landscape
Researchers from Frontiers in Pediatrics examined nearly 800 scientific studies published between 1996 and 2025 on recombinant human growth hormone (rhGH) treatment for children born SGA. What they discovered is that the field has evolved dramatically over three decades, moving from basic questions like "Does this treatment work?" to more sophisticated questions about genetics, personalised medicine, and what actually matters to families.
The research activity has remained steady and strong, with studies being published at a consistent rate of 6.3% growth per year since 2011. This steady progress suggests that doctors and scientists continue to refine and improve how growth hormone therapy is used—a positive sign for parents considering treatment options.
Three Clear Phases of Progress
The research naturally divided into three phases, each aligned with major regulatory approvals. When growth hormone therapy was first approved for SGA children in 2001–2003, early studies focused on proving the treatment was safe and effective. Over time, researchers moved toward understanding the biological mechanisms—the "why" behind growth challenges. Most recently, the field has shifted toward genetic testing and understanding individual differences, plus measuring outcomes that matter to real families: quality of life, confidence, and long-term wellbeing.
This evolution is significant. It means that today's doctors have far better tools to identify which children will benefit most from treatment and to personalise care based on each child's unique genetic profile.
What This Means for Singapore Families
Singapore and Asia benefit from this global research progress. Leading research centres in the Netherlands, the United States, and Germany have collectively published thousands of studies, and paediatricians across Asia draw on these findings daily. The research shows that growth hormone therapy has become increasingly evidence-based and individualised rather than one-size-fits-all.
Importantly, the research reveals a shift toward patient-centred outcomes. Doctors are no longer asking only "How much taller will my child grow?" but also "How will this affect my child's confidence, social development, and quality of life?" This holistic approach aligns well with how many Asian parents think about their children's wellbeing.
The analysis also found that open-access research (studies freely available online) receives significantly more attention from other scientists—2.2 times more citations. This means breakthroughs are spreading faster and more widely, improving care globally.
Three Practical Takeaways for Your Family
- Genetic testing is increasingly important: Modern growth hormone research emphasises genetic diagnostics. If your child is being evaluated for SGA-related growth challenges, ask your paediatrician whether genetic testing could help personalise your child's treatment plan.
- Ask about long-term outcomes beyond height: Contemporary research focuses on how growth hormone therapy affects confidence, social functioning, and quality of life—not just final height. When discussing options with your doctor, ask what these broader outcomes look like for children similar to yours.
- Seek doctors informed by the latest evidence: Choose paediatricians and endocrinologists who stay current with research. The field has matured significantly, and your child deserves care based on the most recent scientific understanding rather than outdated practices.